About

Log in?

DTU users get better search results including licensed content and discounts on order fees.

Anyone can log in and get personalized features such as favorites, tags and feeds.

Log in as DTU user Log in as non-DTU user No thanks

DTU Findit

Conference paper · Journal article

Concern for adverse effects of huperzine a when sold as an ingredient in food supplements

From

National Food Institute, Technical University of Denmark1

Division of Risk Assessment and Nutrition, National Food Institute, Technical University of Denmark2

Research Group for Risk Benefit, National Food Institute, Technical University of Denmark3

Huperzine A is marketed as a cognitive enhancer for healthy individuals when sold as an ingredient in food supplements. Huperzine A is, however, an acetylcholinesterase (AChE) inhibitor with potential for serious adverse health effects if administered in the doses recommended for food supplement use (up to 900 μg/d).

Huperzine A acts by inhibiting AChE, thus preventing the degradation of endogenous acetylcholine, which leads to disrupted neurotransmission that may result in a variety of symptoms such as salivation, defecation, muscle fasciculation, convulsions and death. Purpose: The aim of this study was to make a risk assessment of huperzine A from food supplements based on the available literature.

Method: A systematic review of the literature covering the bibliographic databases SciFinder®, PubMed and Web of ScienceTM was performed to search for toxicological data on huperzine A. Results: Very few toxicological studies were identified in the literature search. However, several articles cite a series of unpublished studies submitted to the FDA as part of an investigational new drug submission.

The study information is sparse and only provides the species, dose range, duration and a short summary of end-points. None of the studies are longer than 180-days. The observed adverse effects can all be related to AChE inhibition but due to the limited information none of the studies are suitable for establishing a health-based guidance value such as an Acute Reference Dose (ARfD) or Acceptable Daily Intake (ADI).

One study in humans showed that administration of 200 μg huperzine A resulted in an erythrocyte AChE-inhibiting activity >20% for almost 5 hours post-dose. A specific cut off value of 20% for brain or erythrocyte AChE inhibition is considered to differentiate between adverse and non-adverse effects.

Huperzine A is under investigation for use as a drug for Alzheimer's disease. Adverse effects like diarrhoea, nausea and vomiting have been reported in these studies, where the investigated doses generally are half the highest dose recommended by vendors of food supplements. Whereas, a certain degree of side effects is accepted for drugs, the same effects should be unacceptable from food supplements intended for healthy individuals.

Language: English
Year: 2018
Pages: S145
Proceedings: 54th Congress of the European Societies of Toxicology
ISSN: 18793169 and 03784274
Types: Conference paper and Journal article
DOI: 10.1016/j.toxlet.2018.06.735
ORCIDs: Bredsdorff, Lea and Pilegaard, Kirsten

DTU users get better search results including licensed content and discounts on order fees.

Log in as DTU user

Access

Analysis